BRN2 (POU3F2) Research Peptide
A research-only peptide derived from the POU3F2 (BRN2) neural transcription factor; mechanistic and phenotypic evidence is limited almost entirely to in vitro and lineage-specification studies. No human therapeutic development, no clinical trials, no established dosing, and no commercial availability through regulated channels.
A short peptide fragment corresponding to a sequence within the POU-domain transcription factor BRN2 (encoded by POU3F2, also called N-Oct3). BRN2 is required for specification and differentiation of cortical upper-layer neurons and of melanocyte progenitors. The peptide has appeared sporadically in preclinical transcription-factor mimetic literature and in nootropic-adjacent grey-market catalogs. There is no coherent clinical development program, no human pharmacokinetic or safety data, and no substantiated therapeutic claim.
Mechanism of action
BRN2 is a class III POU-domain transcription factor required for the specification of upper-layer cortical neurons and of the melanocyte lineage. Short peptides derived from the BRN2 sequence have been studied as tools for probing transcription factor function or as putative cell-penetrating fragments. No coherent cellular or in vivo mechanism of action as a therapeutic peptide has been established.
Primary uses
- Transcription-factor research (in vitro)
- Neuronal differentiation studies (in vitro)
Typical dosing
⚠ No human dosing has ever been established. Any human use would be entirely experimental and unsupported by preclinical safety or efficacy data.
Regulatory status
Not FDA-approved. Not in any registered clinical trial. No therapeutic sponsor. Circulates in grey-market nootropic listings with unverified provenance and purity; any human use would be entirely unregulated and unsupported.
Status as of this entry's last review, October 4, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What we checked
There is no single "BRN2 peptide" in the literature: the name is used for fragments of a neural transcription factor, and no paper indexed on PubMed tests a defined BRN2-derived peptide as a product. This section records what can be checked.
Identity, computed
| Sequence | Not established |
Products sold as BRN2 do not share a published sequence, so none is given. BRN2 itself is the transcription factor POU3F2, a protein of about 440 amino acids.
Regulatory status, read October 5, 2026
Drugs@FDA: 0 records for “BRN2”. EMA medicines list: 0 records for “POU3F2”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.
What the maker or sellers claim
Claim, from research-chemical sellers: a BRN2 peptide supports brain health or mood. No study of any BRN2-derived peptide given to animals or people was found.
About the parent protein, not a peptide
POU3F2 controls how neurons migrate into the layers of the developing cerebral cortex; mice lacking it and its sibling factor have disordered cortical layers (McEvilly et al., 2002). In melanoma, BRN2 is studied as a switch between growth and invasion (Cook et al., 2008). Both are about the protein inside cells, and neither involves giving a peptide fragment.
What we looked for and did not find
No defined peptide, no study of one in any species, no registry record and no regulator record.
| Source | Query | Results, October 5, 2026 | What it was |
|---|---|---|---|
| PubMed | BRN2 peptide | 59 | |
| PubMed | POU3F2 peptide | 32 | |
| ClinicalTrials.gov | POU3F2 | 0 | |
| Drugs@FDA (openFDA) | BRN2 | 0 | |
| EMA medicines list | POU3F2 | 0 |
References
- [pubmed] McEvilly RJ, et al. "Transcriptional regulation of cortical neuron migration by POU domain factors." Science, 2002;295:1528-1532 (BRN2 developmental biology). PMID: 11859196.
- [pubmed] Cook AL, et al. "POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis." Pigment Cell Melanoma Res, 2008;21(6):611-26. PMID: 18983536.
Related peptides
Guides & tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.